Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Accounts payable 413,000 364,900 303,900 195,000 155,139
Product revenue accruals 1,618,900 1,716,400 1,300,800 847,400 781,903
Payroll and benefits 352,100 295,000 246,500 191,300 169,387
Research, development and commercial contract costs 319,200 265,200 198,700 171,600 136,704
Royalty payable 271,000 237,600 215,000 200,400 165,404
Tax related accruals 161,100 99,500 123,300 211,300 104,173
Other 66,300 41,600 42,400 56,600 47,400
Accrued expenses 2,788,600 2,655,300 2,126,700 1,678,600 1,404,971
Milestones payable 32,500 222,500
Contract liabilities 206,800 170,300 159,600 171,700 191,519
Current operating lease liabilities 87,100 33,100 48,600 33,300 10,521
Current finance lease liabilities 5,200 50,600 40,800 46,900 42,434
Other 31,400 50,700 62,500 16,500 72,949
Other current liabilities 363,000 527,200 311,500 268,400 317,423
Current liabilities 3,564,600 3,547,400 2,742,100 2,142,000 1,877,533
Long-term operating lease liabilities 1,544,400 348,600 379,500 377,400 350,463
Long-term finance lease liabilities 112,800 376,100 430,800 509,800 539,042
Tax-related liabilities 698,600 681,400 452,800
Contingent consideration 76,900 77,400 114,400 186,500 189,600
Other 126,300 118,900 118,600 116,800 108,355
Other long-term liabilities 901,800 877,700 685,800 303,300 297,955
Long-term liabilities 2,559,000 1,602,400 1,496,100 1,190,500 1,187,460
Total liabilities 6,123,600 5,149,800 4,238,200 3,332,500 3,064,993
Preferred stock, $0.01 par value; none issued and outstanding
Common stock, $0.01 par value 2,600 2,600 2,600 2,500 2,599
Additional paid-in capital 6,672,400 7,449,700 7,386,500 6,880,800 7,894,027
Accumulated other comprehensive income (loss) 127,800 (14,300) 800 15,900 (68,480)
Retained earnings 9,606,800 10,142,400 6,522,800 3,200,800 858,669
Shareholders’ equity 16,409,600 17,580,400 13,912,700 10,100,000 8,686,815
Total liabilities and shareholders’ equity 22,533,200 22,730,200 18,150,900 13,432,500 11,751,808

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Vertex Pharmaceuticals Inc. current liabilities increased from 2022 to 2023 and from 2023 to 2024.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc. long-term liabilities increased from 2022 to 2023 and from 2023 to 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Vertex Pharmaceuticals Inc. total liabilities increased from 2022 to 2023 and from 2023 to 2024.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Vertex Pharmaceuticals Inc. shareholders’ equity increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.